Orphan Drug Designation, which is granted by the U.S. Food and Drug Administration (FDA), is given to drugs or biologics that are designed to treat, prevent, or diagnose rare conditions. This designation was developed to incentivize drug development within the rare disease sphere. According to reporting from OncLive, the FDA granted Orphan Drug designation to LP-284 for the treatment of high-grade B-cell lymphomas with MYC or BCL2 rearrangements.
To read more about LP-284’s Orphan Drug Designation for the treatment of high-grade B-cell lymphomas, go to PatientWorthy.com here.
Editor’s Note: Get Involved
Cancer doesn’t discriminate. WHATNEXT and its partners are interested in amplifying the voices of those from all identities and backgrounds. If you have a cancer journey to share, reach out here to learn more about how your voice can help spread awareness and inspire individuals from all walks of life.
B-cell lymphoma cancer cancer news lymphoma research treatment
Last modified: February 3, 2025
